Blood for DNA isolation (no sequencing, only SNP array) Stool for microbiome analysis Saliva for microbiome analysis Plasma and serum for metabolomics Urine for creatinine analysis

HIV Infections

Onze Lieve Vrouwe Gasthuis

Radboudumc

Erasmus MC

Elisabeth Twee-Steden ziekenhuis

2000 HIV Human Functional Genomics Partnership Program

Change in liver fibrosis measurement by FibroScan (method by Echosens)

Change in liver steatosis measurement by FibroScan (method by Echosens) and liver ultrasound (method developed by Radboudumc)

Recoring of cadiovascular diseases from patient file:
Stroke/ TIA
Angina pectoris
Myocardial infarction
Claudicatio intermittens
Venous thrombo-embolism
Other …

Genome-wide genotype data including >8 million SNPs per individual

Colonizing microbiome profile will be generated from stool and saliva samples

RNA-sequencing will be performed in PBMCs

Metabolomics analysis by multiplex immunoassays will be performed in plasma or serum

Ex vivo cytokine responses of isolated PBMCs to a range of stimuli (TLR ligands, killed pathogens and viral antigen stimuli)

Extensive phenotyping of circulating immune cells by flow cytometry analysis

Note changes in ECG performed at baseline and two years

Ultrasound measurement of intima-media thickness in the carotid artery as a measure for atherosclerosis and cardiovasculr disease risk.

Radboud University

ViiV Healthcare

Elisabeth-TweeSteden Ziekenhuis

Erasmus Medical Center

Lung Neoplasms

Lung Cancer

Lung Adenocarcinoma

CT surveillance, Lung biopsy, Lung resection

CT scans

Singhealth Institutions

Lung Nodule Prospective Database

Devanand Anantham

Head of Lung Centre

Singapore General Hospital

40 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with chronic lymphocytic leukemia, the most prevalent form of adult leukemia.

LMB-2 in Chronic Lymphocytic Leukemia

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

Response is measured by the 1996 National Cancer Institute (NCI) Working Group Criteria (NCIWG). Complete response is defined as no hepatomegaly, splenomegaly, or lymphadenopathy by physical examination and appropriate radiographic techniques. Lymph nodes must resolve to <1.0cm of 1-1.5cm at baseline, or <1.5cm if >1.5cm at baseline. Partial response is >=50% decrease in peripheral blood lymphocytes count from the pretreatment baseline value. Progressive disease is >=50% increase in the sum of the products of the greatest perpendicular dimensions of a t least 2 lymph nodes on two consecutive examinations 2 weeks apart (at least 1 node must be >=2cm) or appearance of new palpable lymph nodes. Stable disease is characterized by not meeting the above criteria. For additional details about the NCIWG, see the protocol link module.

Response Rate

Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.

Number of Participants With Adverse Events

Overall Study

Robert J. Kreitman, M.D.

Leukemia

Lymphocytic

Chronic

40 micrograms/kg every other day (QOD) x 3 every 4 weeks

lymphadenopathy/ألبيومين

2000 HIV Human Functional Genomics Partnership Program

Lung Nodule Prospective Database

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم